Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac Vaccines and Immunity After Natural SARS-CoV-2 Infection-A Comparative Study from Novi Sad, Serbia

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Feb 2

PMID 35108321

Authors

Vladimir Petrovic

Vladimir Vukovic

Aleksandra Patic

Milos Markovic

Mioljub Ristic

Affiliations

Soon will be listed here.

Abstract

Background: Mass vaccination is the key element in controlling current COVID-19 pandemic. Studies comparing immunogenicity of different COVID-19 vaccines are largely lacking. We aimed at measuring anti-S antibody (Ab) levels in individuals fully vaccinated with BNT162b2, BBIBP-CorV and Gam-COVID-Vac, as well as in COVID-19 convalescents.

Methods: In this cross-sectional study, serum was collected from 400 age- and sex-matched participants, 100 fully vaccinated with BNT162b2, 100 with BBIBP-CorV and 100 with Gam-COVID-Vac on the 28th day after the second vaccine dose, and 100 recovered from COVID-19 at least 28 days after symptom(s) resolution. Sera were analyzed using the LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy). Wilcoxon rank-sum or Kruskal-Wallis tests was used for comparison of Ab levels.

Results: Highest mean value (210.11, SD = 100.42) was measured in the BNT162b2 group, followed by Gam-COVID-Vac (171.11, SD = 120.69) and BBIBP-CorV (68.50, SD = 72.78) AU/mL (p<0.001). Significant differences in antibody levels were found between BNT162b2 and BBIBP-CorV (p<0.001), BNT162b2 and Gam-COVID-Vac (p = 0.001), as well as BBIBP-CorV and Gam-COVID-Vac groups (p<0.001). Percentage of seropositive was 81% in the convalescent group, 83% in BBIBP-CorV vaccinated and 100% in BNT162b2 and Gam-COVID-Vac. When comparing measured antibody levels in vaccinated to those in COVID-19 recovered, significantly higher antibody levels were found for vaccinated with BNT162b2 (p<0.001), and with Gam-COVID-Vac (p<0.001), while for BBIBP-CorV there was no statistically significant difference (p = 0.641).

Conclusions: All three investigated vaccines, BNT162b2, BBIBP-CorV and Gam-COVID-Vac, provide robust immune response 28 days after the second dose of vaccine, in the majority of participants. All individuals vaccinated with BNT162b2 and Gam-COVID-Vac seroconverted, while in vaccinated with BBIBP-CorV and COVID-19 recovered seroconversion rates were lower. Although less potent compared to other two vaccines, immune response after BBIBP-CorV was similar to response measured in convalescents. Challenge still remains to examine dynamics and durability of immunoprotection.

Citing Articles

Effect of Homologous and Heterologous Booster in COVID-19 Vaccination.

Vukcevic M, Despot M, Nikolic-Kokic A, Blagojevic D, Nikolic M, Banko A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770576 PMC: 11679259. DOI: 10.3390/ph17121734.

Effects of Yersinia pseudotuberculosis outer membrane vesicles on Pseudomonas aeruginosa antigens immune response.

Duan Z, Song J, Zhang M, Zhang Z, Li N, Fu Y PLoS One. 2024; 19(12):e0310652.

PMID: 39705292 PMC: 11661608. DOI: 10.1371/journal.pone.0310652.

Comparing the immunogenicity of COVID-19 infection and vaccination in pregnant women as measured by anti-S IgG.

Hemati Z, Ameli S, Nikkhoo B, Shahgheibi S, Seyedoshohadaei F, Soufizadeh N BMC Infect Dis. 2024; 24(1):935.

PMID: 39251937 PMC: 11386373. DOI: 10.1186/s12879-024-09853-5.

Neutralizing antibody responses assessment after vaccination in people living with HIV using a surrogate neutralization assay.

Batchi-Bouyou A, Djontu J, Ingoba L, Mougany J, Mouzinga F, Mbama Ntabi J BMC Immunol. 2024; 25(1):43.

PMID: 38987686 PMC: 11234560. DOI: 10.1186/s12865-024-00625-z.

Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.

Ezzikouri S, Tajudeen R, Majidi H, Redwane S, Aqillouch S, Abdulaziz M Sci Rep. 2024; 14(1):7817.

PMID: 38570577 PMC: 10991243. DOI: 10.1038/s41598-024-58498-6.

References

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J . A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021; 18(2):318-327. PMC: 7786875. DOI: 10.1038/s41423-020-00588-2. View

Jeyanathan M, Afkhami S, Smaill F, Miller M, Lichty B, Xing Z . Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020; 20(10):615-632. PMC: 7472682. DOI: 10.1038/s41577-020-00434-6. View

Luo H, Jia T, Chen J, Zeng S, Qiu Z, Wu S . The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Front Immunol. 2021; 12:632814. PMC: 7982848. DOI: 10.3389/fimmu.2021.632814. View

Roltgen K, Nielsen S, Arunachalam P, Yang F, Hoh R, Wirz O . mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv. 2021; . PMC: 8043478. DOI: 10.1101/2021.04.05.21254952. View

Ristic M, Nikolic N, Cabarkapa V, Turkulov V, Petrovic V . Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia. PLoS One. 2021; 16(2):e0247606. PMC: 7899368. DOI: 10.1371/journal.pone.0247606. View

Olliaro P, Torreele E, Vaillant M . COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe. 2021; 2(7):e279-e280. PMC: 8057721. DOI: 10.1016/S2666-5247(21)00069-0. View

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

Chen Y, Liu Q, Guo D . Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(10):2249. PMC: 7435528. DOI: 10.1002/jmv.26234. View

10.

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

11.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

12.

Yang H, Costa V, Racine-Brzostek S, Acker K, Yee J, Chen Z . Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021; 4(3):e214302. PMC: 7985726. DOI: 10.1001/jamanetworkopen.2021.4302. View

13.

Lamb Y . BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021; 81(4):495-501. PMC: 7938284. DOI: 10.1007/s40265-021-01480-7. View

14.

Guihot A, Litvinova E, Autran B, Debre P, Vieillard V . Cell-Mediated Immune Responses to COVID-19 Infection. Front Immunol. 2020; 11:1662. PMC: 7350607. DOI: 10.3389/fimmu.2020.01662. View

15.

Klasse P, Nixon D, Moore J . Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci Adv. 2021; 7(12). PMC: 7978427. DOI: 10.1126/sciadv.abe8065. View

16.

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani M, Abdulrazzaq N . Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021; 326(1):35-45. PMC: 8156175. DOI: 10.1001/jama.2021.8565. View

17.

Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S . Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021; 26(6). PMC: 7879501. DOI: 10.2807/1560-7917.ES.2021.26.6.2100096. View

18.

Zhao J, Alshukairi A, Baharoon S, Ahmed W, Bokhari A, Nehdi A . Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017; 2(14). PMC: 5576145. DOI: 10.1126/sciimmunol.aan5393. View

19.

Hagen M, Derudder E . Inflammation and the Alteration of B-Cell Physiology in Aging. Gerontology. 2019; 66(2):105-113. DOI: 10.1159/000501963. View

20.

Bertoletti A, Bert N, Qui M, Tan A . SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol. 2021; 18(10):2307-2312. PMC: 8408362. DOI: 10.1038/s41423-021-00743-3. View